Abstracts tagged "prognostic factors and systemic lupus erythematosus (SLE)"

Abstract Number: 784 • 2018 ACR/ARHP Annual Meeting
Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE
Pablo Castaño-Gonzalez¹, Mauricio Restrepo-Escobar^1,2, Laura Morales-Maya¹, Tomás Urrego¹, Simon Sandoval-Alvares¹, Carlos Horacio Muñoz^1,3, Adriana L Vanegas^1,3, Daniel Jaramillo^1,4, Gloria Vasquez¹ and Luis Gonzalez-Naranjo¹, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellin, Colombia, ²Hospital Universitario Pablo Tobon Uribe, Medellin, Colombia, ³Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁴Hospital Universitario de San Vicente Fundación, Medellin, Colombia
Background/Purpose: Patients with SLE have an increased risk of serious infections, including nosocomial infections, which are associated with potentially modifiable adverse outcomes. Our objective is…
Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting
A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
Marco Ulises Martinez-Martinez¹, Cesar Eduardo Vallín Orozco², David Martínez-Galla³ and Carlos Abud-Mendoza⁴, ¹Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ²Rheumatology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ³Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ⁴Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
- Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…
Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting
Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
Abstract Number: 2816 • 2017 ACR/ARHP Annual Meeting
Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score
Md Yuzaiful Md Yusof^1,2, Yasser M El-Sherbiny^1,3, Antonios Psarras¹, Elizabeth M.A. Hensor^1,4, Adewonuola Alase¹, Alaa Mohamed¹, Miriam Wittmann^1,4, Paul Emery^1,4 and Edward M Vital^1,4, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression scoreBackground/Purpose: A period of ANA positivity and other immune…
Abstract Number: 782 • 2016 ACR/ARHP Annual Meeting
Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
Claudia Mendoza Pinto^1,2, Carmelo Pirone³, Ben Parker⁴ and Ian N. Bruce⁵, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Rheumatology Unit, Sapienza University of Rome, Department of Internal Medicine and Medical Specialties,, Rome, Italy, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Mycophenolate mofetil (MMF) is widely used in the treatment of SLE however little is known about factors that may predict response or other outcomes…
Abstract Number: 1818 • 2016 ACR/ARHP Annual Meeting
Predictors for Mortality in Hospitalized Patients with Systemic Lupus Erythematosus from 1999 to 2009: A Follow-up Multicenter Study in China
Xuebing Feng¹, Wenyou Pan², Lin Liu³, Min Wu⁴, Lingyun Sun⁵ and Jiangsu Lupus Collaborative Group, ¹Department of Rheumatology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Huaian First People’s Hospital, Huaian, China, ³Xuzhou No. 4 People’s Hospital, Xuzhou, China, ⁴the 3rd Affiliated Hospital of Suzhou University, Changzhou, China, ⁵the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: To find out prognostic factors predicting the outcome of Chinese patients with systemic lupus erythematosus (SLE) at the time of their first admission. Methods: A…
Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Hironari Hanaoka¹, Hidehiro Yamada², Tomofumi Kiyokawa³, Harunobu Iida¹, Takeshi Suzuki¹, Yoshioki Yamasaki⁴, Seido Ooka⁵, Hiroko Nagafuchi³, Takahiro Okazaki³, Daisuke Ichikawa⁶, Sayuri Shirai⁶, Yugo Shibagaki⁷, Junki Koike⁸ and Shoichi Ozaki³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, ⁸Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
Abstract Number: 2828 • 2016 ACR/ARHP Annual Meeting
Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up
Sejin Byun¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Even though the survival rate among SLE patients has improved over the past few decades, the mortality rate caused by the acute flare of…
Abstract Number: 951 • 2012 ACR/ARHP Annual Meeting
A Systematic Review of Quality of Prognosis Studies in Systemic Lupus Erythematosus
Lily Siok Hoon Lim¹, Senq-J Lee², Brian M. Feldman³, D. D. Gladman⁴, Eleanor Pullenayegum⁵ and Earl D. Silverman⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Pediatric Rheumatology Collaborative Study Group (PRSCG), Toronto, ON, Canada
Background/Purpose: Prognosis studies study future outcomes and/or seek to identify predictive or associative factors associated with outcomes. Strong and consistent prognostic factors can be used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].